MiNK Therapeutics, Inc. (INKT) shares surged 643.52 percent to $57.47 after the publication of a breakthrough case study in Nature's Oncogene highlighted a complete and lasting remission in a patient with advanced testicular cancer treated with the company's iNKT cell therapy, agenT-797.
Shares opened at $21.07 and soared as high as $58.50 on extreme volume of 25.9 million, compared to an average of just 7,585 on the Nasdaq. The stock now sits at the upper end of its 52-week range of $4.56 to $58.50.
The patient had previously failed multiple therapies, including chemotherapy and checkpoint inhibitors, but achieved full remission with a single infusion combined with nivolumab—remaining disease-free for over two years.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.